Form 4: Capricor Therapeutics Director Buys Stock

Director Frank Litvack of Capricor Therapeutics acquired 3,937 shares of common stock for $1.39 per share, increasing his direct holdings.

Summary

• Director Frank Litvack acquired 3,937 shares of Capricor Therapeutics common stock on May 13, 2026, at a price of $1.39 per share.
• Following this transaction, Litvack directly owns 133,776 shares of common stock.
• Additionally, 46,278 shares are held indirectly in a family trust for which Litvack serves as trustee.
• The filing also notes a stock option for 3,937 shares with an exercise price of $1.39, acquired on May 13, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing due to the insider purchase by a director, indicating confidence, but the lack of broader financial performance data limits a stronger positive assessment.

Positives

• Director Frank Litvack increased his direct beneficial ownership of Capricor Therapeutics common stock.
• The acquisition of 3,937 shares at $1.39 per share indicates a belief in the company's value by a key insider.
• The stock option acquired suggests potential future equity participation for management.

Negatives

• The exercise price of the stock option ($1.39) is the same as the purchase price of the common stock, which could indicate a repricing or adjustment event.
• A significant portion of shares (46,278) are held indirectly through a family trust, which may have different implications for direct control or voting.

Risks

• The filing does not explicitly detail risks associated with the transaction itself, but the low per-share price of $1.39 could reflect market sentiment or past performance challenges for Capricor Therapeutics.
• The adjustment of the stock option to reflect a reverse stock split and a share reprice suggests past financial difficulties or restructuring.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the acquisition of stock and options by a director suggests a positive outlook from management regarding the company's future prospects.

Management Comments

• Frank Litvack, as a Director, has increased his direct beneficial ownership in the company.
• The stock option acquired on May 13, 2026, with an exercise price of $1.39, indicates potential future equity participation.

Industry Context

StockSavvy.ai notes that insider transactions, particularly purchases by directors, are often viewed as positive signals by the market, suggesting confidence in the company's valuation and future performance within the biotechnology sector.

Related Party Transactions

• The acquisition of 46,278 shares held indirectly by Frank Litvack through the Litvack Curtis Family Trust represents a related party transaction where the reporting person is a beneficiary and trustee.

Stakeholder Impact

• Shareholders may view the director's purchase positively, signaling confidence in the company's future.
• Employees may be encouraged by insider commitment, potentially boosting morale.
• Creditors and suppliers are not directly impacted by this specific transaction.

Next Steps

• Monitoring of future stock performance and further insider transactions.
• Potential exercise of the stock option by Frank Litvack in the future.

Key Dates

Recommendation

This Form 4 filing indicates a director's purchase of stock, which is generally a positive signal. However, without broader financial results or strategic updates, it's insufficient to warrant a strong buy or sell recommendation. A 'hold' position allows for further monitoring of the company's performance and future disclosures.

Keywords

Capricor Therapeutics, Form 4, Insider Transaction, Stock Acquisition, Director, Common Stock, Stock Option, Beneficial Ownership, SEC Filing